Drug Trial Radar · NCT01096784
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Last checked: Nov 20, 2026Latest source record: Jun 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
121
Actual
Start
Jun 18, 2010
Primary completion
Mar 30, 2016
Study completion Mar 30, 2016
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Mar 31, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, up to 1 day
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the severity of retinopathy of prematurity (ROP) among treated infants with an untreated control population, matched for gestational age at birth while confirming the dose of rhIGF-1/rhIGFBP-3 is safe and efficacious.
Conditions
- Retinopathy of Prematurity (ROP)
Interventions
rhIGF-I/rhIGFBP-3Drug
Continuous intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Severity of Retinopathy of Prematurity (ROP) as Compared to the Severity of ROP in an Untreated Control PopulationTime frame: End of study
Locations
24 sites in 6 countries. Site status is shown where the registry gives one.
University of South Alabama Children's and Women's Hospital
Mobile, Alabama
Univ of California Irvine Med Center
Irvine, California
Georgia Regents Medical Center
Augusta, Georgia
Univ of Mississippi Medical Center
Jackson, Mississippi
Vidant Medical Center
Greenville, North Carolina
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
West Virginia University Hospital
Morgantown, West Virginia
University of Wisconsin - Madison
Madison, Wisconsin
D.A.I. Materno Infantile, S.O.D. Neonatologia e Terapia Intensiva Neonatale - Azienda Ospedaliero-Universitaria Careggi
Florence, Italy
U.O.C Patologia e Terapia Intensiva Neonatale, Istituto Giannina Gaslini-Istituto Pediatrico di Ricovero e Cura a Carattere Scientifico
Genova, Italy
University of Padua
Padua, Italy
Dipartimento per la Tutella della Salute della Donna e della Vita Nascente, del Bambino e dell'Adolescente-U.O.C. Neonatologia-Poli. Gemelli
Rome, Italy
VU medical Center
Amsterdam, Netherlands
Instytut Centrum Zdrowia Matki Polki
Lódz, Poland
Ginekologiczno-Położniczy Szpital Kliniczny Uniwersytetu Medycznego w Poznani
Poznan, Poland
Skånes University Hospital Lund
Lund, Sweden
Karolinska Universtitetssjukhuset i Huddinge
Stockholm, Sweden
Addenbrookes Hospital
Cambridge, United Kingdom
St Peter's Hospital; Ashford & S
Chertsey, United Kingdom
University Hospital
Coventry, United Kingdom
Alder Hey Children's NHS Foundation Trust
Liverpool, United Kingdom
UCL EGA Institute for Women's Health
London, United Kingdom
St. Mary's Hospital
Manchester, United Kingdom
Norfolk and Norwich University
Norwich, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.